Review: Third-generation P2Y12 inhibitors reduce mortality after PCI more than clopidogrel
Related Articles
- 2010 - Review: Third-generation P2Y12 inhibitors reduce mortality after PCI more than clopidogrel. Hillegass, William B. // ACP Journal Club;3/20/2011, Vol. 154 Issue 3, p5
Question Do third-generation P2Y[sub 12] inhibitors reduce mortality more than clopidogrel after percutaneous coronary intervention (PCI)? Review scope Included studies compared third-generation P2Y[sub 12] inhibitors with clopidogrel (or with placebo before clopidogrel in the case of short...
- GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention. Dery, J. P.; Harrington, R. A.; Tcheng, J. E. // Current Pharmaceutical Design;Feb2004, Vol. 10 Issue 4, p387
Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled...
- Acute Coronary Syndrome and its Antithrombotic Treatment: Focus on Aspirin and Clopidogrel Resistance. Bonvini, Robert F.; Reny, Jean-Luc; Mach, François; Zeller, Thomas; Fontana, Pierre // Current Vascular Pharmacology;Apr2009, Vol. 7 Issue 2, p198
Cardiovascular diseases are the most common cause of mortality and morbidity accounting for more than 40% of total mortality in Western countries, most of which is due to acute coronary syndromes (ACS), including ST and non- ST elevation myocardial infarction. An optimal pharmacological approach...
- High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. Geisler, Tobias; Booth, Jean; Tavlaki, Elli; Karathanos, Athanasios; Müller, Karin; Droppa, Michal; Gawaz, Meinrad; Yanez-Lopez, Monica; Davidson, Simon J.; Stables, Rod H.; Banya, Winston; Zaman, Azfar; Flather, Marcus; Dalby, Miles // PLoS ONE;8/28/2015, Vol. 10 Issue 8, p1
Background: Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with high residual platelet reactivity (HRPR) i.e. poor responders, is limited. Objectives: To determine...
- Review of 18 Deaths Thirty Days Following Percutaneous Coronary Intervention at a Low Volume Military Treatment Facility: Decade of Experience. Fentanes, Emilio; Wisenbaugh, Thomas // Hawaii Journal of Medicine & Public Health;Sep2013 Supplement 4, Vol. 72 Issue 9, p52
Background: Quality assurance of percutaneous coronary intervention (PCI) is particularly important at programs where the volume is low (<400 yr/center) as in all Military Treatment Facilities. In addition to statistical analysis of all cardiovascular outcomes, a detailed review of individual...
- Clopidogrel before percutaneous coronary intervention reduced cardiovascular outcome in ST-elevation myocardial infarction. // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p29
The article reports that clopidogrel pretreatment before percutaneous coronary intervention (PCI) reduced cardiovascular outcome in ST-elevation myocardial infarction (MI). Patients in the clopidogrel group had lower rates of the composite endpoint from PCI to 30 days after randomization,...
- Bivalirudin in percutaneous coronary intervention. Caron, Michael F.; McKendall, George R. // American Journal of Health-System Pharmacy;9/15/2003, Vol. 60 Issue 18, p1841
The chemistry and pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, dosing and administration, and pharmacoeconomics of bivalirudin are reviewed; clinical trials of bivalirudin's application in percutaneous coronary intervention (PCI) are also discussed....
- Prasugrel: A Review of its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Duggan, Sean T.; Keating, Gillian M. // Drugs;Aug2009, Vol. 69 Issue 12, p1707
Summary: Prasugrel (Efient®) is a potent, selective and irreversible inhibitor of adenosine diphosphate (ADP)-mediated platelet aggregation that is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) [comprising unstable angina...
- Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial. Lee, Dong-Hyun; Kim, Moo Hyun; Park, Tae-Ho; Park, Jong Sung; Park, Kyungil; Zhang, Hong-Zhe; Seo, Jeong-Min; Lee, Michael S. // Trials;2013, Vol. 14 Issue 1, p1
Background: Patients with reduced responsiveness to clopidogrel often have diminished platelet inhibition, a factor associated with increased rates of major adverse cardiovascular events. Clinical trials that have focused on reducing high on-treatment platelet reactivity (HPR) with an additional...
